2023
Systematic review and meta-analysis: Season of birth and schizophrenia risk
Coury S, Lombroso A, Avila-Quintero V, Taylor J, Flores J, Szejko N, Bloch M. Systematic review and meta-analysis: Season of birth and schizophrenia risk. Schizophrenia Research 2023, 252: 244-252. PMID: 36682315, DOI: 10.1016/j.schres.2022.12.016.Peer-Reviewed Original ResearchConceptsRisk of schizophreniaSummer birthWinter birthSystematic reviewBirth monthVitamin D deficiencyStratified subgroup analysisSchizophrenia riskEtiological risk factorsMonth of birthD deficiencySeason of birthEtiologic causesSubgroup analysisVirus exposureRisk factorsSchizophreniaMonthsBirthSignificant differencesRiskAssociation
2022
Cannabis-based medicine in treatment of patients with Gilles de la Tourette syndrome
Szejko N, Saramak K, Lombroso A, Müller-Vahl K. Cannabis-based medicine in treatment of patients with Gilles de la Tourette syndrome. Neurologia I Neurochirurgia Polska 2022, 56: 28-38. PMID: 34708399, DOI: 10.5603/pjnns.a2021.0081.Peer-Reviewed Original ResearchConceptsCannabis-based medicinesTourette syndromeFirst-line treatmentIntolerable side effectsPresence of motorChildhood-onset disordersLine treatmentTic reductionVocal ticsTherapeutic approachesSide effectsAlternative treatmentElectronic databasesAmerican AcademyBehavioral therapyGilles deOnset disordersEuropean SocietySearch termsRelevant studiesPatientsSyndromeTreatmentSignificant numberAntipsychoticsThe effects of stimulant dose and dosing strategy on treatment outcomes in attention-deficit/hyperactivity disorder in children and adolescents: a meta-analysis
Farhat LC, Flores JM, Behling E, Avila-Quintero VJ, Lombroso A, Cortese S, Polanczyk GV, Bloch MH. The effects of stimulant dose and dosing strategy on treatment outcomes in attention-deficit/hyperactivity disorder in children and adolescents: a meta-analysis. Molecular Psychiatry 2022, 27: 1562-1572. PMID: 35027679, DOI: 10.1038/s41380-021-01391-9.Peer-Reviewed Original ResearchConceptsFixed-dose trialAttention-deficit/hyperactivity disorderDose-limiting adverse eventsChildren/adolescentsAdverse eventsFlexible-dose trialTerms of efficacyClinical practiceHigh dosesFlexible dose designIntolerable adverse eventsHyperactivity disorderIncremental benefitLikelihood of discontinuationADHD symptomsLarge systematic reviewSchool-aged children/adolescentsFlexible titrationPotential long-term effectsSymptom controlTreatment discontinuationClinical outcomesStimulant dosesDaily dosesClinical guidelines